Searched for
AUROBINDO PHARMA QUARTERLY RESULTS FY25
Fortis, Apollo, other hospital stocks slump up to 10% in 2 days after SC questions steep markups. Buying opportunity?Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs and raised concerns o...01 Oct, 2026, 10.35 AM IST- IT companies forecast to post muted second quarterSector leader Tata Consultancy Services and its nearest rival, Infosys, are projected to report weak numbers for the three months ending Se...01 Oct, 2026, 10.30 AM IST
- Jefferies picks 6 hospitals as Buy after steep correction offers 'excellent' entry points. Check target priceJefferies has maintained a Buy rating on six hospital stocks, including Apollo Hospitals and Fortis Healthcare, following a sharp correctio...01 Oct, 2026, 09.17 AM IST
- ET Prime Special Series: Multibagger or IBC - Part 78: A tech company hiding inside an auto-parts maker. But with a weak spotThis is one of the most exciting businesses in the sector: A technology company disguised as an auto-parts maker, growing fast, earning exc...30 Sep, 2026, 08.38 PM IST
- ChrysCapital to take minority stake in Linux laboratoriesLinux Laboratories has secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III. This investment involv...30 Sep, 2026, 01.19 PM IST
- Q2 earnings: Can India Inc repeat Q1, or will Q3 erase the base-effect tailwind?India Inc is likely to see a dip in earnings performance for Q2 in comparison to Q1, with analysts forecasting a growth slowdown of roughly...30 Sep, 2026, 12.43 PM IST
- FIIs dump telecom for 8th straight month, outflows cross Rs 32,000 crore. Are stocks set for rebound?Foreign portfolio investors have dumped Indian telecom stocks for the eighth consecutive month, pulling out over Rs 32,000 crore in CY26. H...30 Sep, 2026, 08.32 AM IST
- KPIT Tech plunges 24% in 3 months as auto demand weakensKPIT Technologies faces a substantial 24% decline in stock value, predominantly due to obstacles in the automotive sector. The company's ne...30 Sep, 2026, 06.43 AM IST
- Two Trades for Today: 2 mid-cap pharma stocks, one for a rise of 6.2%, and the other for a gain of almost 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...29 Sep, 2026, 10.02 PM IST
- CoinSwitch swings to profitability in FY26 as crypto platform’s revenue climbs 150% to Rs 324 croreCoinSwitch achieved profitability based on Adjusted EBITDA for FY26, with revenue growth of 150%. The company's revenue reached Rs 324.19 c...29 Sep, 2026, 07.24 PM IST
- RBI may face two hikes, one dilemma as repo rate is seen hitting 5.75% soon: ReportThe Reserve Bank of India is projected to increase its repo rate by 25 basis points in October and December. Inflationary pressures, primar...29 Sep, 2026, 05.52 PM IST
- Sun Pharma, Aurobindo Pharma, other stocks in focus as Trump exempts India from 100% tariffs on some speciality drugsIndian pharma stocks, including Sun Pharma and Aurobindo Pharma, are in focus after the US exempted India and 19 other countries from 100% ...29 Sep, 2026, 08.56 AM IST
- Goldman Sachs sees Eternal achieving $1 billion EBITDA by FY29; raises target priceGoldman Sachs maintained a Buy rating on Eternal, formerly Zomato, raising its target price by 11% to Rs 385. The brokerage foresees Eterna...29 Sep, 2026, 08.30 AM IST
- HSBC expects RBI to raise repo rate by 50 bps in FY27 amid strong growth, inflation pressuresIndia's GDP growth in the second quarter of FY26 surpassed the Reserve Bank of India's forecast of 7 percent. The growth prompted forecasts...28 Sep, 2026, 01.43 PM IST
- Jagsonpal Pharma to acquire Group Pharma’s wellness portfolioJagsonpal Pharmaceuticals has signed a business transfer agreement to acquire the wellness portfolio of Group Pharmaceuticals. The acquisit...24 Sep, 2026, 06.44 PM IST
- Meesho shares rally 12% after UBS hikes target price by 24%. What’s keeping analysts bullish?UBS has raised its Meesho estimates across NMV, contribution profit and EBITDA, citing stronger seller and buyer growth and improving unit ...22 Sep, 2026, 12.14 PM IST
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...16 Sep, 2026, 02.39 PM IST
Load More
